| ITRM:Iterum Therapeutics PLC * | | Charting | News | Options |
*Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements |
||||||||||||
| ||||||||||||||
| ||||||||||||||
| ||||||||||||||
0.00% $0.00
 Markets |
 Portfolio |
| |
| |
|
| |
|
|
|
|||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||
|
| Latest Story |
|
| Thinking about buying stock in Akebia Therapeutics, Mind Medicine, ATAI Life Sciences, Doma Holdings, or Iterum Therapeutics? |
|
| PR Newswire |
|
InvestorsObserver issues critical PriceWatch Alerts for AKBA, MNMD, ATAI, DOMA, and ITRM. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. |
| Full Story → |
|
| Headline News |
|
| Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results |
| 7:00a ET March 28 '24 GlobeNewswire |
|
|
| Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 |
| 4:30p ET March 21 '24 GlobeNewswire |
|
|
| Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat |
| 8:00a ET March 15 '24 GlobeNewswire |
|
| More News → |
| ||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
| April 19 '24. Markets Closed. | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
| Previous data from yesterday, April 18 '24. | ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| Historical Price Performance | ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
Market data provided by 
News provided by   |
9.49%
118% 
